Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Auxly Cannabis Group Inc. (XLY.TO)
Toronto, ON, CA
Auxly Cannabis Group Inc. operates as a Canadian consumer packaged goods (CPG) firm focused on the cannabis market. Its primary activities include the development, manufacturing, and distribution of cannabis products, targeting both recreational and wellness consumers. The company offers a wide array of cannabis formats under its distinct brands—KOLAB PROJECT, Dosecann, BACK FORTY, and Foray—including vape cartridges, dried flower, concentrates, chocolates, soft chews, oil drops, capsules, topicals, and hard candy. Originally incorporated in 1987, the company was known as Cannabis Wheaton Income Corp. before officially changing its name to Auxly Cannabis Group Inc. in June 2018. It is headquartered in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.67% | +3.70% | -3.45% | +16.67% | -9.68% | -3.45% | +64.71% | +833.33% | -56.25% | -89.27% | -89.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+23.8% ★ Q1'26: +21.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+294.1% ★ Q1'26: -75.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+25.2% Q1'26: +28.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+25.7% ★ Q1'26: -12.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+19.2% ★ Q1'26: -10.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+31.7% Q1'26: +18.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.15× Q1'26: -6.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
747.0K
est: 2.36M (-68.3%)
|
8.35M
est: 6.20M (+34.7%)
|
46.72M
est: 45.10M (+3.6%)
|
83.83M
est: 85.08M (-1.5%)
|
94.47M
est: 93.80M (+0.7%)
|
101.08M
est: 95.00M (+6.4%)
|
122.33M
est: 110.50M (+10.7%)
|
151.48M
est: 152.20M (-0.5%)
|
164.50M
164.50M – 164.50M
+8.1% YoY
|
174.40M
174.40M – 174.40M
+6.0% YoY
|
| EBITDA |
-55.99M
est: -970.6K (-5,668.3%)
|
-98.90M
est: -2.55M (-3,772.1%)
|
-64.59M
est: -18.58M (-247.6%)
|
-18.30M
est: -35.05M (+47.8%)
|
-94.79M
est: -38.64M (-145.3%)
|
-10.89M
est: -39.14M (+72.2%)
|
24.38M
est: -17.56M (+238.8%)
|
50.31M
est: -24.19M (+308.0%)
|
-26.14M
-26.14M – -26.14M
-8.1% YoY
|
-27.72M
-27.72M – -27.72M
-6.0% YoY
|
| EBIT |
-58.05M
est: -1.15M (-4,956.6%)
|
-107.48M
est: -3.02M (-3,457.6%)
|
-73.59M
est: -21.98M (-234.9%)
|
-32.57M
est: -41.45M (+21.4%)
|
-114.98M
est: -45.71M (-151.6%)
|
-22.10M
est: -46.29M (+52.3%)
|
14.10M
est: -27.30M (+151.6%)
|
38.86M
est: -37.61M (+203.3%)
|
-40.64M
-40.64M – -40.64M
-8.1% YoY
|
-43.09M
-43.09M – -43.09M
-6.0% YoY
|
| Net Income |
-66.99M
est: -60.23M (-11.2%)
|
-102.57M
est: -96.37M (-6.4%)
|
-85.43M
est: -120.46M (+29.1%)
|
-33.74M
est: -36.14M (+6.6%)
|
-130.29M
est: -168.64M (+22.7%)
|
-44.51M
est: -36.14M (-23.2%)
|
-16.35M
est: -15.87M (-3.0%)
|
41.86M
est: 47.60M (-12.1%)
|
15.87M
15.87M – 15.87M
-66.7% YoY
|
15.87M
15.87M – 15.87M
+0.0% YoY
|
| SGA |
41.32M
est: 1.31M (+3,060.0%)
|
45.49M
est: 3.44M (+1,221.9%)
|
46.11M
est: 25.03M (+84.2%)
|
45.42M
est: 47.22M (-3.8%)
|
50.38M
est: 52.06M (-3.2%)
|
40.28M
est: 52.73M (-23.6%)
|
40.73M
est: 47.09M (-13.5%)
|
49.07M
est: 64.85M (-24.3%)
|
70.10M
70.10M – 70.10M
+8.1% YoY
|
74.31M
74.31M – 74.31M
+6.0% YoY
|
| EPS |
-0.14
est: -0.05 (-180.0%)
|
-0.18
est: -0.08 (-125.0%)
|
-0.14
est: -0.10 (-40.0%)
|
-0.06
est: -0.03 (-95.3%)
|
-0.15
est: -0.14 (-7.1%)
|
-0.04
est: -0.03 (-49.7%)
|
-0.01
est: -0.01 (-36.0%)
|
0.03
est: 0.03 (+5.0%)
|
0.01
0.01 – 0.01
-66.7% YoY
|
0.01
0.01 – 0.01
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hugo Alves | Chief Executive Officer & Director | 695.5K | male |
| Michael David Lickver | President | 515.4K | male |
| Travis Wong | Chief Financial Officer | 392.1K | male |
| Ron Fichter | General Counsel & Corporate Secretary | 361.1K | male |
| Andrew MacMillan | Senior Vice President of Commercial | 347.8K | male |
| Kevin Furet | Chief Cultivation & Genetics Officer | — | male |
| Vladimir Klacar | Senior Vice President of Operations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XLY.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
